Maze Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	-	167.5	-	-
Gross Profit	-	167.5	-	-
Selling, General & Admin	31.47	26.42	24.61	22.83
Research & Development	103.09	83.5	73.95	88.19
Operating Expenses	134.57	109.91	98.55	111.03
Operating Income	-134.57	57.59	-98.55	-111.03
Interest & Investment Income	9.8	4.65	1.97	2.03
Earnings From Equity Investments	-	-	-	-3.54
EBT Excluding Unusual Items	-124.76	62.24	-96.59	-112.54
Gain (Loss) on Sale of Investments	-	-	-	-2.4
Other Unusual Items	-1.64	-8.84	-3.83	-
Pretax Income	-126.41	53.4	-100.42	-114.94
Income Tax Expense	-0.28	1.17	-	-
Net Income	-126.13	52.23	-100.42	-114.94
Preferred Dividends & Other Adjustments	-24.67	48.83	-	-
Net Income to Common	-101.46	3.41	-100.42	-114.94
Shares Outstanding (Basic)	30	2	2	2
Shares Outstanding (Diluted)	30	3	2	2
Shares Change (YoY)	1176.31%	19.33%	13.82%	-
EPS (Basic)	-3.36	1.42	-43.89	-57.18
EPS (Diluted)	-3.39	1.25	-43.89	-57.18
Free Cash Flow	-108.03	74.81	-87.27	-101.17
Free Cash Flow Per Share	-3.58	27.40	-38.14	-50.33
Gross Margin	-	100.00%	-	-
Operating Margin	-	34.38%	-	-
Profit Margin	-	2.03%	-	-
Free Cash Flow Margin	-	44.66%	-	-
EBITDA	-131.96	60.88	-94.46	-107.21
EBITDA Margin	-	36.35%	-	-
D&A For EBITDA	2.61	3.3	4.09	3.82
EBIT	-134.57	57.59	-98.55	-111.03
EBIT Margin	-	34.38%	-	-
Effective Tax Rate	-	2.20%	-	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q